Introduction
A number of ammine, amine and heterocyclic complexes of ruthenium exhibit: inhibition of DNA replication, 'a mutagenic activity, induction of the SOS repair mechanism, 3 binding to nuclear DNA, 4 by charging with fewer nitrogen ligands and more halides to yield a more soluble anionic complex. 8- An early working hypothesis regarding the design of Ru-anticancer agents suggested a tumor selectivity based upon preferential reduction of RulII-prodrugs in the more reducing environment of tumors. ,a The Ru II oxidation state should also be more prevalent inside of tumors, because in the hypoxic milieu of tumors there is less oxygen to oxidize Ru II back to the Ru III state. 13 '14 Such "activation by reduction" in the tumor would favor intracellular binding by the more rapidly substituting Ru II ion. Since unprotonated imines are a preferred binding site for RuII, the concentration of such sites in the N7 of purines in nucleic acids suggests DNA as a preferred target. Srivastava showed that some ruthenium complexes, such as RuC13, were transported to the tumor by transferdn. 5 Clarke suggested that multiacido ruthenium(III)complexes, particularly anionic or neutral complexes with lower ligand field stabilization energies and more rapid substitution rates, might also be transported in the blood by transferrin. 16 (Table I) .
The effect of transferrin on cell toxicity and DNA binding of the ruthenium complexes was studied by running cultures with added apotransferrin ([Tf]a) under normal atmospheric conditions. Transferrin in the media itself is -3.3 gM. As added apotransferrin enhances cell growth at low concentrations, but inhibits cell growth at [Tf]a > 0.7 gM (50 gg/mL), the effect of apotransferrin was studied over the range 0 0.7 gM (see Figure 8) (Figure 7 , see Table I) are linear indicating increased toxicity through increased DNA binding at lower oxygen tensions for both complexes. While the effect of transferrin is higher for ICR, both drugs exhibit significantly increased toxicity relative to the controls as the apotransferrin concentration increases (Figure 8 ). As the data were treated by linear methods, the positive intercepts on many of the DNA binding curves (Figs. 2, 4 and 6) are artifacts of the statistical treatment, but are also consistent with an active transport mechanism providing entry for these complexes into the HeLa cells.
As (Table I) .
While the reduction potential at neutral pH (E' -262 mV) 26, 27 of ICR is within a biologically accessible range, significant reduction is not expected. However, reduction of ICR is pH dependent and becomes more favored at lower pH. 8 At pH 5, which results when protons are pumped into the endosomes to release Fe III (and presumably RuIII) from the Fetransferrin-receptor complex, 9'29 the reduction potential for ICR is ---100 mV. Reduction should also be facilitated by loss of chloride (tl/2 3.5 h at 37 C), rather than anionic charge. It may be that imidazoles by virtue of their ability to serve as rt---dr-donors or dn---rt-acceptors (depending on the energy and extension of the d-orbitals) 27 help to provide a polarizable site for proton addition, which raises the reduction potential of the metal ion.
As the concentration of apotransferrin increases (with no Ru), cell growth initially increases and then gradually decreases, so that at added concentrations greater than 50 tg/ mL, transferrin itself is toxic. When the effect of added apotransferrin was studied within the range of approximately normal cell growth at [Ru] = 10 gM, growth inhibition increased as the apotransferrin concentration increased. Since transferrin is known to bind ICR, such behavior for this complex is not surprising. The observation of similar behavior for CCR, suggests that CCR also enters cancer cells by a transferrin-mediated route and that this is comparable in efficiency to that for ICR.
The similarity in transferrin effects may be due to the comparable aquation rates of the two complexes. At 37' C CCR substitutes water for chloride at a rate of 3.5 x 10 -5 s-1 (t1/2 5.5 h), 3 while that for ICR is 5.3 x 10 -5 s -1 (t1/2 = 3.7 h). 28 Considering that cellular uptake and transfer into the cell nucleus precedes DNA binding, these substitution rates seem slow in accounting for the amount of ruthenium binding to the intracellular DNA. More rapid substitution is consistent with an activation-by-reduction pathway.
Conclusion
Both cationic (CCR) and anionic (ICR) antitumor complexes behaved remarkably similarly, suggesting analogous mechanisms of action, which probably involves transferrin binding to actively transport the Ru into the cancer cell, possibly followed by intracellular activation by reduction to facilitate DNA binding. On average for the various oxygen tensions and for both complexes, IC50's occur when one ruthenium is coordinated per 1000-2000 DNA base pairs.
